文献速递造血干细胞移植与细胞治疗白血病

急性淋巴细胞白血病患者接受单倍体联合移植后环磷酰胺与全相合无关供者移植的结局比较

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.
PubMed 文献 · Blood Adv · 2020-01-01

比较2005年1月至2018年6月间1461例成人急性淋巴细胞白血病患者接受单倍体(487例)或全相合无关供者(MUD,974例)造血干细胞移植的结局。单倍体受者按1:2与MUD对照匹配。多中心病例匹配回顾性分析显示,单倍体移植结局与8/8 MUD移植相当。

要点

  • 清髓性预处理后第+28天中性粒细胞恢复:单倍体87% vs MUD 88%(P=0.11)。
  • 3年总生存率清髓性方案:单倍体44% vs MUD 51%(P=0.56);减低强度预处理:43% vs 42%(P=0.6)。
  • 3个月II-IV级急性GVHD和3年慢性GVHD发生率在单倍体与MUD间相似。

核心结论

  • 在这项大型多中心病例匹配回顾性分析中,尽管存在登记研究局限性(如缺乏微小残留病检测等关键要素),急性淋巴细胞白血病患者接受单倍体供者移植的结局与8/8全相合无关供者移植相当。

研究设计与样本

  • 多中心病例匹配回顾性分析,纳入2005年1月至2018年6月间1461例接受造血干细胞移植的成人急性淋巴细胞白血病患者,单倍体供者487例,全相合无关供者974例。
  • 单倍体受者按1:2比例与MUD对照进行匹配,匹配因素包括性别、预处理强度、疾病分期、费城染色体状态和细胞遗传学风险。
  • 单倍体移植的GVHD预防方案为移植后环磷酰胺(PTCy)、钙调神经磷酸酶抑制剂(CNI)和吗替麦考酚酯(MMF);MUD移植为CNI联合MMF或甲氨蝶呤,联合或不联合抗胸腺球蛋白。

主要发现

  • 清髓性预处理后第+28天中性粒细胞恢复率:单倍体87% vs MUD 88%(P=0.11);减低强度预处理后分别为84% vs 88%(P=0.47)。
  • 清髓性预处理后3个月II-IV级急性GVHD发生率:单倍体33% vs MUD 34%(P=0.46);3年慢性GVHD发生率:单倍体29% vs MUD 31%(P=0.58)。
  • 减低强度预处理后3个月II-IV级急性GVHD发生率:单倍体31% vs MUD 30%(P=0.06);3年慢性GVHD发生率:单倍体24% vs MUD 29%(P=0.86)。
  • 清髓性预处理后3年总生存概率:单倍体44% vs MUD 51%(P=0.56);减低强度预处理后分别为43% vs 42%(P=0.6)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出登记研究存在局限性,即无法获取微小残留病检测等关键要素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We compared outcomes of 1461 adult patients with acute lymphoblastic leukemia (ALL) receiving hematopoietic cell transplantation (HCT) from a haploidentical (n = 487) or matched unrelated donor (MUD; n = 974) between January 2005 and June 2018. Graft-versus-host disease (GVHD) prophylaxis was posttransplant cyclophosphamide (PTCy), calcineurin inhibitor (CNI), and mycophenolate mofetil (MMF) for haploidentical, and CNI with MMF or methotrexate with/without antithymoglobulin for MUDs. Haploidentical recipients were matched (1:2 ratio) with MUD controls for sex, conditioning intensity, disease stage, Philadelphia-chromosome status, and cytogenetic risk. In the myeloablative setting, day +28 neutrophil recovery was similar between haploidentical (87%) and MUD (88%) (P = .11). Corresponding rates after reduced-intensity conditioning (RIC) were 84% and 88% (P = .47). The 3-month incidence of grade II-IV acute GVHD (aGVHD) and 3-year chronic GVHD (cGVHD) was similar after haploidentical compared with MUD: myeloablative conditioning, 33% vs 34% (P = .46) for aGVHD and 29% vs 31% for cGVHD (P = .58); RIC, 31% vs 30% (P = .06) for aGVHD and 24% vs 29% for cGVHD (P = .86). Among patients receiving myeloablative regimens, 3-year probabilities of overall survival were 44% and 51% with haploidentical and MUD (P = .56). Corresponding rates after RIC were 43% and 42% (P = .6). In this large multicenter case-matched retrospective analysis, despite the limitations of a registry-based study (ie, unavailability of key elements such as minimal residual disease testing), our analysis indicated that outcomes of patients with ALL undergoing HCT from a haploidentical donor were comparable with 8 of 8 MUD transplantations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Al Malki MM, Yang D, Labopin M, et al. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv. 2020. PMID: 32396617. doi:10.1182/bloodadvances.2020001499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。